|
ZA201804004B
|
|
Modified antigen binding molecules with altered cell signaling activity
|
|
AU2015213405A1
|
|
Anti-FAP antibodies and methods of use
|
|
AU2014247175A1
|
|
Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
|
|
HUE047925T2
|
|
Bispecific t cell activating antigen binding molecules specific to cd3 and cea
|
|
MX2015010789A
|
|
Anti-mcsp antibodies.
|
|
WO2014131711A1
|
|
Bispecific t cell activating antigen binding molecules
|
|
CN110845618A
|
|
Bispecific T cell activating antigen binding molecules
|
|
WO2014114595A1
|
|
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
|
EP2925780A1
|
|
Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
|
|
EP2904016A1
|
|
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
CN109705218A
|
|
ASGPR antibody and application thereof
|
|
AR092044A1
|
|
IMPROVED IMMUNOTHERAPY
|
|
SG11201408526SA
|
|
Interleukin-10 fusion proteins and uses thereof
|
|
MA37794A1
|
|
Anti-vegf / anti-ang-2 bispecific antibodies and their use in the treatment of ocular vascular pathologies
|
|
AU2013203431A1
|
|
Bispecific death receptor agonistic antibodies
|
|
WO2014161570A1
|
|
Antibodies against human il17 and uses thereof
|
|
US2013273032A1
|
|
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
|
WO2013113641A1
|
|
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
|
US2013302274A1
|
|
Combination therapy
|
|
CN103906842A
|
|
In vivo ADCC model
|
